# EDGAR Filing Document

**Accession Number:** 0001174940
**File Stem:** 0000000000-25-006353
**Filing Date:** 2025-6
**Character Count:** 8698
**Document Hash:** bf62969f3db059a61c512f191f34c290
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-006353.hdr.sgml**: 20250902

**ACCESSION NUMBER**: 0000000000-25-006353

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250617

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ORAGENICS INC
- **CENTRAL INDEX KEY:** 0001174940
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 593410522
- **STATE OF INCORPORATION:** FL
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 377-08072

**BUSINESS ADDRESS:**
- **STREET 1:** 1990 MAIN STREET
- **STREET 2:** SUITE 750
- **CITY:** SARASOTA
- **STATE:** FL
- **ZIP:** 34236
- **BUSINESS PHONE:** 8132867900

**MAIL ADDRESS:**
- **STREET 1:** 1990 MAIN STREET
- **STREET 2:** SUITE 750
- **CITY:** SARASOTA
- **STATE:** FL
- **ZIP:** 34236
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001641172-25-013316

## Text-Extract

```

                                                            June 17, 2025

Janet Huffman
Chief Executive Officer
Oragenics, Inc.
1990 Main Street, Suite 750
Sarasota, FL 34236

       Re: Oragenics, Inc.
           Draft Registration Statement on Form S-1
           Submitted June 3, 2025
           CIK No. 0001174940
Dear Janet Huffman:

       We have reviewed your draft registration statement and have the
following comments.

       Please respond to this letter by providing the requested information and
either
submitting an amended draft registration statement or publicly filing your
registration
statement on EDGAR. If you do not believe a comment applies to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

      After reviewing the information you provide in response to this letter
and your
amended draft registration statement or filed registration statement, we may
have additional
comments.

Draft Registration Statement on Form S-1
Cover Page

1.     Please revise here and in the section captioned Determination of
Offering Price on
       page 28 to explain how you determined the $25.00 offering price per unit
of Series H
       Convertible Preferred Stock and accompanying Warrant, and the assumed
conversion
       price of $3.60 per share. If either the offering price per unit or the
conversion price
       has been arbitrability determined, please state this clearly throughout
the
       prospectus and add risk factor disclosure to this effect as appropriate,
or otherwise
       advise.
2.     Please revise here and in the section captioned "Description of
Securities We are
       Offering" to disclose the conversion ratio at which the Series H
Convertible Preferred
       Stock will convert into shares of Common Stock. Explain how the
Conversion Price
 June 17, 2025
Page 2

       adjustment provisions may impact future conversion ratio(s) and
therefore the number
       of Common Shares that may become issuable upon conversion of the Series
H
       Preferred and Warrants.
3.     Please revise the cover page, the Summary, and the section captioned
"Description of
       Securities We Are Offering" to highlight that the Certificate of
Designation for the
       Series H Convertible Preferred Stock contains anti-dilution provisions
that may result
       in the reset and reduction of the Conversion Price for the Preferred
Stock if you enter
       into a future financing transaction that triggers lowering the
Conversion Price. If true,
       explain that because the Conversion Price is not subject to any floor,
future
       conversions could result in an indeterminate increased number of shares
of Common
       Stock being issued. Include clear disclosure regarding the operation of
any such
       provisions that will impact the number of shares of Common Stock to be
issuable
       upon conversion, and explain the impact to the Company if you may not
have
       sufficient available shares available to satisfy the future conversion
of the Preferred
       Stock and the dilutive impact to shareholders. Additionally, discuss the
effect of this
       offering on your ability to raise additional capital.
Risk Factors, page 13

4.     We note your disclosure that you effectuated a one-for-thirty reverse
stock split of
       your issued and outstanding Common Stock on June 3, 2025. If true,
include risk
       factor disclosure explaining that this offering could cause the Company
 s common
       stock price to fall below the minimum bid price, which could result in
its shares being
       delisted from the NYSE American. In such risk factor, describe the
decrease in the
       value of your Common Stock pre-split, and include discussion of your
decision to
       effect the one-for-thirty reverse stock split in order to increase the
price per share. If
       applicable, describe any potential limitations on the Company's ability
to use a reverse
       stock split to regain compliance with the minimum price criteria again
in the future.
5.     We note that your auditor has expressed substantial doubt about your
ability to
       continue as a going concern. Please add a risk factor describing the
potential effect
       that this conclusion may have on your ability to raise additional funds
through equity
       or debt financing, as well as the potential terms of any such
financings. In this regard,
       we note that under the terms of the Certificate of Designation for the
Series H
       Convertible Preferred Stock, the Conversion Price may be impacted by the
price at
       which you issue your securities in future financings.
The market price of our Common Stock may never exceed the Conversion Price of
the
Preferred Stock., page 17

6.     Please revise to provide context for your disclosure that the market
price of your
       Common Stock may never exceed the Conversion Price prior to the
expiration of the
       Warrants. If true, explain in such case the unlikelihood that the
Company will receive
       significant proceeds from exercises of the Warrants.
Use of Proceeds, page 18

7.     We note that you intend to use the net proceeds from this offering "to
fund [y]our
       ongoing ONP-2 concussion clinical trials, along with other related
research and
 June 17, 2025
Page 3

       development activities, to repay the $3 million Bridge Note, as well as
for working
       capital and other general corporate purposes." In this regard:
           Please revise to disclose how far into the development process you
anticipate such
          proceeds will enable you to reach. Although we note your disclosure
that the net
          proceeds from this offering will not be sufficient for you to fund
your ONP-002
          product candidate through regulatory approval, please clarify whether
you
          anticipate being able to fund your Phase 2a and Phase 2b trials with
the proceeds
          from this offering.
           Please revise this section to disclose the interest rate and
maturity of the Bridge
          Note. Refer to Instruction 4 to Item 504 of Regulation S-K.
           As this is a best efforts offering with no minimum offering amount,
please revise
          your disclosure to explain how proceeds will be allocated (1) in the
event you
          raise less than the full $18.25 million, assuming no exercise of the
Warrants, and
          (2) in the event you raise less than the full $3 million needed to
repay the Bridge
          Note at maturity.
           As appropriate, include risk factor disclosure related to the Bridge
Note
          maturity and any impact to the Company if the Bridge Note is not
repaid in full or
          in part using the offering proceeds, or otherwise advise. For
example, discuss how
          the repayment of the Bridge Loan would impact the cash you have
available for
          other purposes and to execute your business strategy.
Information Incorporated by Reference, page 31

8.     Please incorporate by reference your Quarterly Report on Form 10-Q for
the
       period ended March 31, 2025, as filed on May 9, 2025. Refer to Item
12(a)(2) of Form
       S-1.
       Please contact Lauren Hamill at 303-844-1008 or Tim Buchmiller at
202-551-3635
with any other questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:   Julio Esquivel, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._